You have access
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
HIDEKAZU KURAMOCHI, TAKESHI YAMADA, YOICHIRO YOSHIDA, AKIHISA MATSUDA, HIROHIKO KAMIYAMA, CHIHIRO KOSUGI, KEIICHIRO ISHIBASHI, ATSUKO FUKAZAWA, KEISUKE IHARA, HIROMICHI SONODA, KAZUHIKO YOSHIMATSU, HIROSHI YOSHIDA, SUGURU HASEGAWA, KAZUHIRO SAKAMOTO, HIDEYUKI ISHIDA, KEIJI KODA and On behalf of the TAS CC3 Study Group
Anticancer Research June 2021, 41 (6) 3131-3137; DOI: https://doi.org/10.21873/anticanres.15098